anle138b
Nucleic acidexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 6, 2019 (NCT04208152)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Prion proteinANTISENSE INHIBITOR
PRIO antisense inhibitor
- Alpha-synucleinANTISENSE INHIBITOR
SNCA antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05532358 | Phase 1 | Sep 12, 2022 | Aptuit Inc., MODAG GmbH, Quotient, Teva |
| NCT04685265 | Phase 1 | Dec 31, 2020 | Aptuit Inc., MODAG GmbH, Quotient, University of Nottingham |
| NCT04208152 | Phase 1 | Dec 6, 2019 | Aptuit Inc., MODAG GmbH, Quotient |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aptuit Inc. | For profit | 3 | 0 | 1 | 2019 |
| MODAG GmbH | For profit | 3 | 3 | 1 | 2019 |
| Quotient | For profit | 3 | 0 | 1 | 2019 |
| Teva | For profit | 1 | 0 | 1 | 2022 |
| University of Nottingham | Academic/Hospital | 1 | 0 | 1 | 2020 |
5 organizations
Page 1 / 1